Legend Biotech (LEGN) Share-based Compensation (2020 - 2026)

Legend Biotech (LEGN) has 7 years of Share-based Compensation data on file, last reported at $19.3 million in Q1 2026.

• Quarterly Share-based Compensation rose 21.38% year-over-year to $19.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.0 million (up 4.26% YoY) and the FY2024 annual result came in at $68.9 million, up 44.59% from the prior year.
• Share-based Compensation rose to $19.3 million in Q1 2026, from $15.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $21.7 million in Q2 2024 to a low of $5.7 million in Q1 2022.
• A 5-year average of $13.7 million and a median of $14.2 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation jumped 164.58% — and 2025, when it decreased 14.99%.
• Tracing LEGN's Share-based Compensation over 5 years: stood at $9.0 million in 2022, then soared by 40.3% to $12.6 million in 2023, then grew by 6.35% to $13.4 million in 2024, then advanced by 12.15% to $15.0 million in 2025, then climbed by 28.54% to $19.3 million in 2026.
• The last three Share-based Compensation figures came in at $19.3 million (Q1 2026), $15.0 million (Q3 2025), and $18.7 million (Q2 2025), per Business Quant data.